- Active not recruitingPHASE2
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
This study looks at a new drug, pembrolizumab, combined with standard chemotherapy for children and young adults (3-25 years old) with newly diagnosed classical Hodgkin Lymphoma. It specifically focuses on those who aren't responding quickly to initial treatment.
For: Hodgkin LymphomaUnited States · Brazil · Colombia - RecruitingPHASE3
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
This study is for people with early-stage Hodgkin Lymphoma. It compares two chemotherapy treatments, ABVD and A2VD, to see which works best. Treatment is adjusted based on scans, and patients are followed for at least 5 years.
For: Hodgkin LymphomaUnited States · Australia · Belgium - Ongoing, recruitingTherapeutic exploratory (Phase II)
Vascular changes in basal cell carcinoma undergoing electrochemotherapy or photodynamic therapy - assessed with optical coherence tomography
This study looks at how treatments for a common type of skin cancer (basal cell carcinoma), affect the tiny blood vessels in the skin. Researchers use a special camera to see these changes, aiming to improve how we treat this cancer without surgery.
For: basal cell carcinomaDenmark - AuthorisedTherapeutic exploratory (Phase II)
ORGAN SPARING FOR LOCALLY ADVANCED RECTAL CANCER AFTER NEOADJUVANT TREATMENT FOLLOWED BY ELECTROCHEMOTHERAPY - LARC_ DEEP_CANCERS
This study looks at a new way to treat bowel cancer that has spread nearby, using a drug called bleomycin and electric pulses. The aim is to see if this treatment can help avoid surgery and improve outcomes for patients, potentially leading to faster recovery and fewer side effects.
For: colorectal cancerItaly - Active not recruitingPHASE1, PHASE2
A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)
This study looks at a new drug, Nivolumab, combined with standard treatment (ABVD) for Hodgkin lymphoma. The goal is to improve the chances of a cure, especially for people with higher-risk forms of the disease. It checks if adding Nivolumab helps when initial treatment doesn't fully clear the cancer.
For: Hodgkin LymphomaUnited States · Canada